Kestra Medical Technologies Ltd

Kestra Medical Technologies Ltd(KMTS)股票分析

$28.320

+1.048 (+3.70%)收盘时

Loading chart…
最高
29.200
开盘
27.615
成交量加权均价
28.27
成交量
738.83K
市值
—
最低
27.280
成交额
20.88M
企业价值/息税折旧摊销前利润(TTM)
-7.39

Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.

AI 分析 of Kestra Medical Technologies Ltd (KMTS)

买入

Kestra Medical Technologies is a good buy right now due to its significant revenue growth of 60% year-over-year, increasing from $19.37 million to $30.97 million, and a gross margin improvement to 56.5%, which is up over 10 percentage points year-over-year. The main risk is the widening net loss of $44.09 million for Q1 2027, which could impact investor sentiment.

估值指标

Kestra Medical Technologies Ltd(KMTS)当前预期市盈率为 0.00,5 年平均预期市盈率为 -9.68。

预期市盈率

严重高估
5 年均值 P/E
-9.68
当前P/E
0.00
高估
-6.54
低估
-12.82

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-10.33
当前EV/EBITDA
-7.39
高估
-4.05
低估
-16.61

预期市销率

合理
5 年均值 P/S
10.75
当前P/S
8.60
高估
14.12
低估
7.38

持有 KMTS 的大户

J

Jaunty Global Limited

+ 持有KMTS

+2.88%

3个月收益率

事件时间线

2026-09-15 (ET)

09:00:00

Stock Futures Lower Ahead of Fed Policy Meeting

2026-09-14 (ET)

19:30:00

Anthropic CEO Warns of Out-of-Control AI, Tech Stocks Plunge

17:00:00

Kestra Medical Shares Down 7% to $22.32 After Q1 Earnings Miss

16:30:00

Kestra Raises FY27 Revenue Guidance to $141 Million

16:30:00

Kestra Reports Q1 Revenue of $30.97M, Exceeding Expectations

资讯

KMTS 常见问题 —— 由 Alphio AI 解答

Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG. It operates in the Healthcare sector.

Kestra Medical Technologies is a good buy right now due to its significant revenue growth of 60% year-over-year, increasing from $19.37 million to $30.97 million, and a gross margin improvement to 56.5%, which is up over 10 percentage points year-over-year. The main risk is the widening net loss of $44.09 million for Q1 2027, which could impact investor sentiment.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易